Amy Cheung1, Anthony Levitt1, Michael Cheng2, Darcy Santor3, Stan Kutcher4, Elyse Dubo1, E Jane Garland5, Margaret Weiss5, Alex Kiss1. 1. University of Toronto, Toronto, Ontario; Sunnybrook Health Sciences Centre, Toronto, Ontario. 2. University of Ottawa, Ottawa, Ontario; Children's Hospital of Eastern Ontario, Ottawa, Ontario. 3. University of Ottawa, Ottawa, Ontario. 4. Dalhousie University, Halifax, Nova Scotia. 5. University of British Columbia, Vancouver, British Columbia.
Abstract
PURPOSE: To examine the benefit of continuation treatment with citalopram in adolescents 13 to 18 years of age with major depression using a multi-site randomized placebo controlled discontinuation design. METHODS:Subjects with depression who responded to open label treatment with citalopram in 12-week acute phase were randomized to continued treatment with citalopram or placebo for 24 weeks. RESULTS:Twenty five subjects were randomized to either continued treatment with citalopram (n = 12) versus placebo (n = 13). Seventy-five percent of subjects on citalopram (75%) remained well as compared to placebo (62%). Time to relapse was compared between groups using the log rank test and was not found to be significantly different (χ(2)(1) = 0.35, P = 0.55). A Cox proportional hazards model including drug assignment (hazard ratio (HR = 0.51, 95% CI 0.11 to 2.36, P = 0.39), gender (HR = 0.58, 95% CI 0.14 to 2.37, P = 0.44), or HAM-score at entry to continuation phase (HR = 1.33, 95% CI 0.90 to 1.95, P = 0.95) was not significant. CONCLUSION: Although we did not find statistically significant differences between citalopram and placebo, the findings suggest a possible benefit of continued treatment with citalopram over placebo. A larger clinical trial with adequate power is required to confirm or disconfirm these findings.
RCT Entities:
PURPOSE: To examine the benefit of continuation treatment with citalopram in adolescents 13 to 18 years of age with major depression using a multi-site randomized placebo controlled discontinuation design. METHODS: Subjects with depression who responded to open label treatment with citalopram in 12-week acute phase were randomized to continued treatment with citalopram or placebo for 24 weeks. RESULTS: Twenty five subjects were randomized to either continued treatment with citalopram (n = 12) versus placebo (n = 13). Seventy-five percent of subjects on citalopram (75%) remained well as compared to placebo (62%). Time to relapse was compared between groups using the log rank test and was not found to be significantly different (χ(2)(1) = 0.35, P = 0.55). A Cox proportional hazards model including drug assignment (hazard ratio (HR = 0.51, 95% CI 0.11 to 2.36, P = 0.39), gender (HR = 0.58, 95% CI 0.14 to 2.37, P = 0.44), or HAM-score at entry to continuation phase (HR = 1.33, 95% CI 0.90 to 1.95, P = 0.95) was not significant. CONCLUSION: Although we did not find statistically significant differences between citalopram and placebo, the findings suggest a possible benefit of continued treatment with citalopram over placebo. A larger clinical trial with adequate power is required to confirm or disconfirm these findings.
Authors: J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-07 Impact factor: 8.829
Authors: Graham J Emslie; Beth D Kennard; Taryn L Mayes; Jeanne Nightingale-Teresi; Thomas Carmody; Carroll W Hughes; A John Rush; Rongrong Tao; Jeanne W Rintelmann Journal: Am J Psychiatry Date: 2008-02-15 Impact factor: 18.112
Authors: John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe Journal: JAMA Date: 2004-08-18 Impact factor: 56.272
Authors: David A Brent; Laurence L Greenhill; Scott Compton; Graham Emslie; Karen Wells; John T Walkup; Benedetto Vitiello; Oscar Bukstein; Barbara Stanley; Kelly Posner; Betsy D Kennard; Mary F Cwik; Ann Wagner; Barbara Coffey; John S March; Mark Riddle; Tina Goldstein; John Curry; Shannon Barnett; Lisa Capasso; Jamie Zelazny; Jennifer Hughes; Sa Shen; S Sonia Gugga; J Blake Turner Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-10 Impact factor: 8.829
Authors: Boris Birmaher; David Brent; William Bernet; Oscar Bukstein; Heather Walter; R Scott Benson; Allan Chrisman; Tiffany Farchione; Laurence Greenhill; John Hamilton; Helene Keable; Joan Kinlan; Ulrich Schoettle; Saundra Stock; Kristin Kroeger Ptakowski; Jennifer Medicus Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-11 Impact factor: 8.829
Authors: Sarah E Hetrick; Joanne E McKenzie; Alan P Bailey; Vartika Sharma; Carl I Moller; Paul B Badcock; Georgina R Cox; Sally N Merry; Nicholas Meader Journal: Cochrane Database Syst Rev Date: 2021-05-24
Authors: Andrea Monsour; Emma J Mew; Sagar Patel; Alyssandra Chee-A-Tow; Leena Saeed; Lucia Santos; Darren B Courtney; Priya N Watson; Suneeta Monga; Peter Szatmari; Martin Offringa; Nancy J Butcher Journal: BMC Med Res Methodol Date: 2020-05-25 Impact factor: 4.615